Addex Regains Full Global Rights to GABAB PAM Portfolio from Indivior
ADXN sits 19% above its 52-week low of $3.1 on light trading volume (0.1× avg).
Summary
Addex Therapeutics regained full global rights to its GABAB PAM portfolio from Indivior, including a substance-use-disorder candidate that completed IND-enabling studies, and now controls one of the broadest GABAB portfolios in the industry.
Key Events · M&A and Partnerships · ADXN
-
Full Rights to GABAB PAM Portfolio Regained
Addex regained full global rights to all GABAB PAM assets discovered under its research collaboration with Indivior UK Limited, following Indivior's R&D rationalization and the planned merger of Indivior's parent with Supernus Pharmaceuticals.
-
Returned Candidate Completed IND-Enabling Studies
The returned development candidate for substance use disorders has successfully completed IND-enabling studies, positioning it for potential clinical advancement.
-
Broadest GABAB Portfolio in Industry
Combined with Addex's wholly owned GABAB PAM program for chronic cough, the returned asset gives the company one of the broadest portfolios targeting GABAB receptor biology, with potential applications across substance use disorders, chronic cough, pain, overactive bladder, and neurodevelopmental disorders.
-
Strategic Flexibility for Partnerships
Addex can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering, with freedom to pursue therapeutic indications beyond those originally contemplated under the agreement.
Analysis · ADXN · Life Sciences
Regaining full ownership of its GABAB PAM assets removes a partner dependency for Addex, following Indivior's R&D rationalization and planned merger with Supernus. The company now has the freedom to pursue new partnerships or advance the programs independently. The returned substance-use-disorder candidate has completed IND-enabling studies, and combined with the chronic cough program, Addex now holds one of the broadest GABAB portfolios in the industry. For a micro-cap company with a market cap near $3.5 million, regaining control of a clinically validated mechanism with multiple potential indications is a meaningful strategic shift.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADXN was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $3.10 to $12.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.